Logo image of SUPN

SUPERNUS PHARMACEUTICALS INC (SUPN) Stock Fundamental Analysis

NASDAQ:SUPN - Nasdaq - US8684591089 - Common Stock - Currency: USD

33.815  +0.7 (+2.1%)

Fundamental Rating

7

SUPN gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. SUPN gets an excellent profitability rating and is at the same time showing great financial health properties. SUPN scores decently on growth, while it is valued quite cheap. This could make an interesting combination. With these ratings, SUPN could be worth investigating further for value and quality investing!.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

SUPN had positive earnings in the past year.
In the past year SUPN had a positive cash flow from operations.
SUPN had positive earnings in each of the past 5 years.
In the past 5 years SUPN always reported a positive cash flow from operatings.
SUPN Yearly Net Income VS EBIT VS OCF VS FCFSUPN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

1.2 Ratios

SUPN has a Return On Assets of 4.60%. This is amongst the best in the industry. SUPN outperforms 88.08% of its industry peers.
SUPN's Return On Equity of 6.01% is amongst the best of the industry. SUPN outperforms 86.01% of its industry peers.
With an excellent Return On Invested Capital value of 4.82%, SUPN belongs to the best of the industry, outperforming 82.38% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for SUPN is significantly below the industry average of 14.87%.
The 3 year average ROIC (2.70%) for SUPN is below the current ROIC(4.82%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 4.6%
ROE 6.01%
ROIC 4.82%
ROA(3y)3.02%
ROA(5y)4.13%
ROE(3y)4.71%
ROE(5y)7.54%
ROIC(3y)2.7%
ROIC(5y)4.37%
SUPN Yearly ROA, ROE, ROICSUPN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

SUPN's Profit Margin of 9.27% is amongst the best of the industry. SUPN outperforms 86.53% of its industry peers.
SUPN's Profit Margin has declined in the last couple of years.
SUPN's Operating Margin of 12.49% is amongst the best of the industry. SUPN outperforms 83.42% of its industry peers.
In the last couple of years the Operating Margin of SUPN has declined.
With an excellent Gross Margin value of 89.75%, SUPN belongs to the best of the industry, outperforming 93.26% of the companies in the same industry.
In the last couple of years the Gross Margin of SUPN has remained more or less at the same level.
Industry RankSector Rank
OM 12.49%
PM (TTM) 9.27%
GM 89.75%
OM growth 3Y-9.85%
OM growth 5Y-18.4%
PM growth 3Y6.61%
PM growth 5Y-17.27%
GM growth 3Y0.96%
GM growth 5Y-1.32%
SUPN Yearly Profit, Operating, Gross MarginsSUPN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

7

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), SUPN is destroying value.
SUPN has more shares outstanding than it did 1 year ago.
SUPN has more shares outstanding than it did 5 years ago.
SUPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SUPN Yearly Shares OutstandingSUPN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
SUPN Yearly Total Debt VS Total AssetsSUPN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

SUPN has an Altman-Z score of 5.14. This indicates that SUPN is financially healthy and has little risk of bankruptcy at the moment.
SUPN's Altman-Z score of 5.14 is fine compared to the rest of the industry. SUPN outperforms 78.76% of its industry peers.
There is no outstanding debt for SUPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 5.14
ROIC/WACC0.49
WACC9.9%
SUPN Yearly LT Debt VS Equity VS FCFSUPN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.3 Liquidity

A Current Ratio of 2.44 indicates that SUPN has no problem at all paying its short term obligations.
The Current ratio of SUPN (2.44) is comparable to the rest of the industry.
SUPN has a Quick Ratio of 2.26. This indicates that SUPN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.26, SUPN is in line with its industry, outperforming 46.63% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.44
Quick Ratio 2.26
SUPN Yearly Current Assets VS Current LiabilitesSUPN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

6

3. Growth

3.1 Past

SUPN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 98.54%, which is quite impressive.
SUPN shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 3.78% yearly.
The Revenue has grown by 11.81% in the past year. This is quite good.
Measured over the past years, SUPN shows a quite strong growth in Revenue. The Revenue has been growing by 11.00% on average per year.
EPS 1Y (TTM)98.54%
EPS 3Y37.36%
EPS 5Y3.78%
EPS Q2Q%69.23%
Revenue 1Y (TTM)11.81%
Revenue growth 3Y4.51%
Revenue growth 5Y11%
Sales Q2Q%4.3%

3.2 Future

Based on estimates for the next years, SUPN will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.42% on average per year.
Based on estimates for the next years, SUPN will show a small growth in Revenue. The Revenue will grow by 7.28% on average per year.
EPS Next Y-31.87%
EPS Next 2Y-2.58%
EPS Next 3Y10.68%
EPS Next 5Y15.42%
Revenue Next Year-0.44%
Revenue Next 2Y5.61%
Revenue Next 3Y7.56%
Revenue Next 5Y7.28%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SUPN Yearly Revenue VS EstimatesSUPN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
SUPN Yearly EPS VS EstimatesSUPN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2 4 6

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

SUPN is valuated correctly with a Price/Earnings ratio of 12.43.
Based on the Price/Earnings ratio, SUPN is valued cheaper than 89.12% of the companies in the same industry.
SUPN is valuated cheaply when we compare the Price/Earnings ratio to 27.41, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 14.03, which indicates a correct valuation of SUPN.
SUPN's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. SUPN is cheaper than 79.79% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 35.19. SUPN is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 12.43
Fwd PE 14.03
SUPN Price Earnings VS Forward Price EarningsSUPN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, SUPN is valued cheaply inside the industry as 94.30% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, SUPN is valued cheaper than 89.64% of the companies in the same industry.
Industry RankSector Rank
P/FCF 11.59
EV/EBITDA 6.38
SUPN Per share dataSUPN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

The excellent profitability rating of SUPN may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)3.29
EPS Next 2Y-2.58%
EPS Next 3Y10.68%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SUPN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SUPERNUS PHARMACEUTICALS INC

NASDAQ:SUPN (7/14/2025, 3:56:09 PM)

33.815

+0.7 (+2.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-06 2025-05-06/amc
Earnings (Next)07-31 2025-07-31/amc
Inst Owners108.96%
Inst Owner Change0%
Ins Owners4.08%
Ins Owner Change2.14%
Market Cap1.89B
Analysts78.18
Price Target39.78 (17.64%)
Short Float %7.57%
Short Ratio7.65
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)46.36%
Min EPS beat(2)15.55%
Max EPS beat(2)77.18%
EPS beat(4)3
Avg EPS beat(4)60.49%
Min EPS beat(4)-9.5%
Max EPS beat(4)158.74%
EPS beat(8)5
Avg EPS beat(8)41.41%
EPS beat(12)6
Avg EPS beat(12)18.01%
EPS beat(16)9
Avg EPS beat(16)24.4%
Revenue beat(2)1
Avg Revenue beat(2)4.64%
Min Revenue beat(2)-0.71%
Max Revenue beat(2)9.98%
Revenue beat(4)3
Avg Revenue beat(4)7.41%
Min Revenue beat(4)-0.71%
Max Revenue beat(4)10.86%
Revenue beat(8)5
Avg Revenue beat(8)3.48%
Revenue beat(12)8
Avg Revenue beat(12)2.47%
Revenue beat(16)11
Avg Revenue beat(16)2.27%
PT rev (1m)0.52%
PT rev (3m)0.52%
EPS NQ rev (1m)-6%
EPS NQ rev (3m)2.92%
EPS NY rev (1m)-18.23%
EPS NY rev (3m)-13.58%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.1%
Revenue NY rev (1m)2.26%
Revenue NY rev (3m)2.62%
Valuation
Industry RankSector Rank
PE 12.43
Fwd PE 14.03
P/S 2.83
P/FCF 11.59
P/OCF 11.53
P/B 1.84
P/tB 4.6
EV/EBITDA 6.38
EPS(TTM)2.72
EY8.04%
EPS(NY)2.41
Fwd EY7.13%
FCF(TTM)2.92
FCFY8.63%
OCF(TTM)2.93
OCFY8.67%
SpS11.93
BVpS18.41
TBVpS7.35
PEG (NY)N/A
PEG (5Y)3.29
Profitability
Industry RankSector Rank
ROA 4.6%
ROE 6.01%
ROCE 7.83%
ROIC 4.82%
ROICexc 8.53%
ROICexgc N/A
OM 12.49%
PM (TTM) 9.27%
GM 89.75%
FCFM 24.45%
ROA(3y)3.02%
ROA(5y)4.13%
ROE(3y)4.71%
ROE(5y)7.54%
ROIC(3y)2.7%
ROIC(5y)4.37%
ROICexc(3y)4.39%
ROICexc(5y)6.6%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)4.82%
ROCE(5y)7.36%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y11.61%
ROICexc growth 5Y-8.56%
OM growth 3Y-9.85%
OM growth 5Y-18.4%
PM growth 3Y6.61%
PM growth 5Y-17.27%
GM growth 3Y0.96%
GM growth 5Y-1.32%
F-Score8
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 1%
Cap/Sales 0.12%
Interest Coverage -758.75
Cash Conversion 100.39%
Profit Quality 263.83%
Current Ratio 2.44
Quick Ratio 2.26
Altman-Z 5.14
F-Score8
WACC9.9%
ROIC/WACC0.49
Cap/Depr(3y)0.67%
Cap/Depr(5y)5.39%
Cap/Sales(3y)0.09%
Cap/Sales(5y)0.25%
Profit Quality(3y)2940.94%
Profit Quality(5y)1832.68%
High Growth Momentum
Growth
EPS 1Y (TTM)98.54%
EPS 3Y37.36%
EPS 5Y3.78%
EPS Q2Q%69.23%
EPS Next Y-31.87%
EPS Next 2Y-2.58%
EPS Next 3Y10.68%
EPS Next 5Y15.42%
Revenue 1Y (TTM)11.81%
Revenue growth 3Y4.51%
Revenue growth 5Y11%
Sales Q2Q%4.3%
Revenue Next Year-0.44%
Revenue Next 2Y5.61%
Revenue Next 3Y7.56%
Revenue Next 5Y7.28%
EBIT growth 1Y1176.19%
EBIT growth 3Y-5.79%
EBIT growth 5Y-9.43%
EBIT Next Year84.48%
EBIT Next 3Y-11.94%
EBIT Next 5Y21.99%
FCF growth 1Y0.95%
FCF growth 3Y11.03%
FCF growth 5Y4.05%
OCF growth 1Y1.58%
OCF growth 3Y10.6%
OCF growth 5Y3.74%